| 1 |
Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology, 2008, 48(1): 308-321.
|
| 2 |
Sandhu DS, Roberts LR. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep, 2008, 10(1): 43-52.
|
| 3 |
Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford), 2008, 10(2): 77-82.
|
| 4 |
Chekulayeva LV, Chekulayev VA, Shevchuk IN. Active oxygen intermediates in the degradation of hematoporphyrin derivative in tumor cells subjected to photodynamic therapy. J Photochem Photobiol B, 2008, 93(2): 94-107.
|
| 5 |
Wainwright M. Photodynamic therapy: the development of new photosensitisers. Anticancer Agents Med Chem, 2008, 8(3): 280-291.
|
| 6 |
Kiesslich T, Krammer B, Plaetzer K. Cellular mechanisms and pros pective applications of hypericin in photodynamic therapy. Curr Med Chem, 2006, 13(18): 2189-2204.
|
| 7 |
Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy(PDT). Photochem Photobiol Sci, 2004, 3(8): 765-771.
|
| 8 |
Dumoulin FL, Gerhardt T, Fuchs S, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003;57(7):860-867.
|
| 9 |
Stukavec J, Horak L, Duchac V，et al. Comparison of photodynamic therapy with phthalocyanine and photofrin in human colorectal carcinoma. Neoplasma, 2008, 55(2): 127-129.
|
| 10 |
Corti L, Toniolo L, Boso C，et al. Long-term survival of patients treated with photodynamic therapy for carcinoma in situ and early non-small-cell lung carcinoma. Lasers Surg Med, 2007, 39(5): 394-402.
|
| 11 |
Allison RR, Bagnato VS, Cuenca R, et al. The future of photodynamic therapy in oncology. Future Oncol, 2006, 2(1): 53-71.
|
| 12 |
Ortner MA. Photodynamic therapy in cholangiocarcinomas. Best Pract Res Clin Gastroenterol, 2004, 18(1): 147-154.
|
| 13 |
Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology, 1998, 114(3):536-542.
|
| 14 |
Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11): 2426-2430.
|
| 15 |
Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer, 2003, 97(11): 2783-2790.
|
| 16 |
Ferrario A, Fisher AM, Rucker N, et al. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors. Cancer Res, 2005, 65(20): 9473-9478.
|
| 17 |
陈锡林, 汪谦, 江穗, 等. 蛋白酶体抑制剂Velcade诱导肝癌细胞HepG2凋亡[J/CD]. 中华普通外科学文献:电子版, 2008, 2(5): 358-362.
|
| 18 |
Cao LQ, Chen XL, Wang Q, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin, 2007, 28(6): 879-887.
|